Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several safety/side-effect prevalence and symptom-causation claims are not supported by the provided FDA label excerpts; some indications are supported (cholesterol lowering and cardiovascular disease prevention), but overall adherence is poor due to multiple unsupported quantitative and mechanistic statements.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to lower cholesterol levels.
Label mechanism/clinical pharmacology: “Clinical and pathologic studies show... elevated plasma levels of total cholesterol... LDL-cholesterol... promote... atherosclerosis...” and clinical studies: “LIPITOR reduces total-C, LDL-C... and increases HDL-C.” (Sections 12.1, 14.2)
Lipitor (atorvastatin) is used to prevent cardiovascular diseases.
Indications: “In adult patients... with multiple risk factors... LIPITOR is indicated to: Reduce the risk of myocardial infarction... Reduce the risk of stroke... Reduce the risk for revascularization procedures and angina...” (Section 1.1) and CHD indications (Section 1.1)
Severe muscle pain or weakness (myopathy) while taking Lipitor is a symptom for which to seek immediate medical attention.
Label discusses myopathy/rhabdomyolysis as serious adverse reactions (Sections 5.1, 6). Note: the label excerpts do not include the exact instruction “seek immediate medical attention,” so support is partial for the seriousness concept.
Unsupported Statements
Immediate fatigue (feeling tired or exhausted soon after taking Lipitor/atorvastatin) is a potential side effect that some individuals experience.
The provided label excerpts do not mention fatigue/tiredness as an adverse reaction; only specific common adverse reactions are listed (e.g., myalgia, diarrhea, nausea, ALT/ hepatic enzyme increases).
Fatigue was reported by 12.6% of patients taking atorvastatin (Lipitor) in the first 30 days of treatment.
No label excerpt provided includes this quantitative incidence for fatigue.
Approximately 20-30% of people taking Lipitor report experiencing fatigue or tiredness as a side effect.
No label excerpt provided includes this range or any incidence data for fatigue/tiredness.
Muscle pain or weakness (myopathy) is a possible cause of fatigue while taking Lipitor.
The label excerpt supports myopathy/rhabdomyolysis as adverse reactions, but does not state that myopathy causes fatigue.
Muscle damage (rhabdomyolysis) is a possible cause of fatigue while taking Lipitor.
The label excerpt supports rhabdomyolysis as a serious adverse reaction, but does not state rhabdomyolysis causes fatigue.
Sleep disturbances are a possible cause of fatigue while taking Lipitor.
No label excerpt provided mentions sleep disturbances or their relationship to fatigue.
Anxiety or depression are possible causes of fatigue while taking Lipitor.
No label excerpt provided mentions anxiety/depression or their relationship to fatigue.
Interactions with other medications are a possible cause of fatigue while taking Lipitor.
The label excerpt mentions drug interactions increasing the risk of myopathy (e.g., with certain drugs), but does not state fatigue is caused by interactions.
Severe muscle pain or weakness while taking Lipitor is a symptom for which to seek immediate medical attention.
While the label excerpt notes serious myopathy/rhabdomyolysis, it does not provide the specific patient-instruction wording about “immediate medical attention.”
Difficulty breathing while taking Lipitor is a symptom for which to seek immediate medical attention.
No label excerpt provided includes this symptom or an instruction for it.
Chest pain or discomfort while taking Lipitor is a symptom for which to seek immediate medical attention.
No label excerpt provided includes this symptom or an instruction for it.
Weakness or tingling in the arms or legs while taking Lipitor is a symptom for which to seek immediate medical attention.
No label excerpt provided includes this symptom or an instruction for it.
Contradictions
Important Omissions
Boxed warnings (if present) and other specific warnings/precautions beyond muscle/liver dysfunction are not addressed in the AI claims.
Importance:
Moderate
Risk-related monitoring recommendations (e.g., liver function tests prior to and at 12 weeks after initiation and after dose increases) are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported prevalence and symptom-causation statements (e.g., fatigue incidence and linking fatigue to myopathy/rhabdomyolysis, sleep disturbance, anxiety/depression) could mislead readers, although some broad seriousness guidance for muscle symptoms aligns conceptually with labeled serious muscle adverse reactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple fatigue-related prevalence and causation claims are not supported by the provided FDA label excerpts; several urgent-care symptom instructions are also not present in the provided label text.
Suggested Improvement
Remove or revise fatigue-specific incidence (e.g., 12.6%, 20–30%) and causal links (fatigue due to myopathy/rhabdomyolysis, sleep/anxiety/depression, or drug interactions) unless supported by label text. For urgent symptom guidance, use label-supported serious adverse reactions and avoid adding specific symptom-and-action pairings that are not explicitly described in the provided label excerpts.